<DOC>
	<DOCNO>NCT02345291</DOCNO>
	<brief_summary>A multicenter , Phase 2a , randomize , double-blind , placebo ( vehicle ) -controlled , parallel-group , dose-finding study design evaluate efficacy , safety tolerability NRD135S.E1 adult patient diabetes mellitus type 1 2 neuropathic pain . Potential study patient sign inform consent prior undergoing study-related procedure .</brief_summary>
	<brief_title>Effect NRD135S.E1 Peripheral Neuropathic Pain Diabetic Patients</brief_title>
	<detailed_description>Following screening , eligible patient enrol go week washout analgesic treatment . Patients still eligible follow washout randomize one four treatment group : NRD135S.E1 10 , 40 , 150 mg per day placebo ( vehicle ) . All four treatment group start study treatment 1 week single blind placebo ( baseline week ) follow 3 week allocate double blind treatment ( Weeks 1 , 2 , 3 ) . All patient follow 30 day last study drug administration . The total study duration per patient 9 to10 week . Visit schedule : Screening ( Days minus 14 minus 8 , Visit 1 ) . Washout visit ( Day minus 7 , Visit 2 ) . Randomization start placebo treatment ( Day 1 , Visit 3 ) . Double blind treatment visit Days 8 ( Visit 4 ) , 15 ( Visit 5 ) 29 ( Visit 6 ) . Follow visit telephone ( Day 59 , Visit 7 ) .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>1 . Males agree use condom throughout treatment follow study period . Females must childbearing potential evidence least one following : ≥ 62 year old amenorrheic ≥ 1 year Amenorrheic ≥ 12 consecutive month document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL Irregular menstrual period document FSH level &gt; 35 mIU/mL On hormone replacement therapy prior clinical evidence menopause base criterion Surgically sterile 2 . Known stable diabetes mellitus last 3 month . ( No oral hypoglycemic medication change allow . Maximum insulin change allow ± 20 % ) . 3 . Evidence peripheral neuropathy associate diabetes mellitus diagnose DN4 criterion . 4 . Presence ongoing pain due DPN least 3 month . 5 . Mean DPN pain intensity 4 9 NPS screening . 6 . HbA1c ≤ 9 % total hemoglobin screening . 7 . Willing stop pain medication DPN ( except limit use paracetamol ) . 8 . Signed write informed consent . Subjects must sign dated Institutional Review Board / Independent Ethics Committee approve write informed consent form accordance regulatory institutional guideline . This must obtain performance protocol relate procedure part normal subject care . Subjects must willing able comply schedule visit , treatment schedule , laboratory testing , requirement study . Exclusion Criteria 1 . Female childbearing potential . 2 . Neurologic disorder unrelated DPN may interfere assessment DPN . 3 . Known allergy intolerance paracetamol . 4 . Evidence nonDPN polyneuropathy . 5 . The presence severe pain associated condition DPN ( e.g. , peripheral vascular disease , phantom pain , etc . ) could confound selfevaluation pain due DPN . 6 . Any antiepileptic antidepressive treatment . Amityptiline ( Elatrol/Elatrolet ) duloxetine ( Cymbalta ) permit screen later . 7 . Constant use nonsteroidal antiinflammatory drug opiates withdraw washout period whole study duration . 8 . Participation another clinical trial last 3 month . 9 . Poor compliance prescribe medication alcohol drug abuse within 2 year screen . 10 . Hypersensitivity paracetamol inactive ingredient NRD135S.E1 capsule . 11 . Any serious medical condition , include presence laboratory abnormality , place patient unacceptable risk participates study confounds ability interpret data study . 12 . Patients hematological disorder . 13 . Prisoners subject involuntarily incarcerate . 14 . Subjects compulsorily detain treatment either psychiatric physical ( e.g . infectious disease ) illness . 15 . Patients whose judgment impair physical ir mental condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>